Ergothioneine and Cataract Prevention

Ergothioneine & Eye Health

3 protective mechanisms

Cataractous human lens tissue contains markedly lower ergothioneine than normal lenses — a real but unreplicated 1981 observation that is routinely overstated into a prevention claim the evidence does not support.

Shukla et al., Indian J Med Res, 1981

Avascular

the lens has no blood supply and depends on the aqueous humor for antioxidants

ETT / OCTN1

the dedicated ergothioneine transporter — cells without it cannot accumulate ergothioneine at all

Nrf2 pathway

activated by ergothioneine under UV-induced oxidative stress, in skin and cell models

Shukla et al., Indian J Med Res, 1981

View as image ↗

In 1981, researchers examined the ergothioneine content of human cataractous lens tissue and found something striking: cataract patients had markedly less of it than age-matched people with healthy vision.^[1] That connection between ergothioneine and cataract prevention wasn't well understood at the time, but the data was unambiguous. Cataractous lenses were depleted.

What makes this observation meaningful today is everything learned since about how ergothioneine moves through the body. The lens cannot accumulate ergothioneine passively — cell membranes are essentially impermeable to it. Reaching lens tissue at measurable concentrations requires active, transporter-mediated uptake. That is a real biological cost for a tissue under severe oxidative stress, and it is the strongest available hint that the compound is there for a reason.

For a broader survey of how ergothioneine interacts with all eye tissues, Ergothioneine for Eye Health: Research and Implications covers the full evidence landscape. If you're new to the compound, ergothioneine is an unusual amino acid found almost exclusively in mushrooms that the human body specifically hoards in tissues under oxidative stress.

Lens Proteins That Last 70 Years: Why Oxidative Damage Is Permanent

The lens of the eye has a property unlike almost any other tissue: its proteins are never replaced. The crystallin proteins synthesized before and around birth remain in the lens for the rest of a person's life. No turnover. No repair through replacement.

When those proteins oxidize, they aggregate and begin scattering light rather than transmitting it. The result, accumulating over years or decades, is the progressive cloudiness called a cataract.

This makes the lens extraordinarily vulnerable to cumulative oxidative damage. Most tissues handle oxidative injury by replacing damaged proteins. The lens cannot. Every molecule of damage that escapes antioxidant neutralization in real time becomes a permanent structural change. The proteins present at age 70 carry the record of every oxidative hit that wasn't stopped.

Ultraviolet light is the primary driver. When UV radiation enters the eye, the lens absorbs a substantial portion before the light reaches the retina. That absorption generates singlet oxygen and hydrogen peroxide directly in the lens tissue. Both oxidize crystallin proteins. Both lead, over time, to the aggregation and cloudiness that defines a cataract.

Cataracts are the leading cause of reversible blindness globally. The core mechanism is oxidative protein damage accumulating over a lifetime in a tissue that cannot clear it. Any antioxidant system that reduces that burden continuously, in real time, over decades, has the potential to delay that accumulation.

A Lens With No Blood Supply Still Gets Ergothioneine

The lens has no blood vessels. It receives nutrients and antioxidants exclusively from the aqueous humor, the clear fluid circulating in the front chamber of the eye.

This creates a fundamental problem. Most antioxidants that circulate in the bloodstream don't reach the lens efficiently. Passive diffusion through the aqueous humor is too slow to maintain the concentrations the lens needs to defend against continuous UV bombardment. The lens has to do something active if it wants reliable antioxidant protection.

The solution is active transport. Epithelial surfaces in the eye express transporter proteins that pull specific molecules from the surrounding fluid against their concentration gradient. The body spends metabolic energy on this because passive diffusion can't meet the demand.

For ergothioneine specifically, this is not optional. Gründemann's 2005 characterization showed that cells lacking the ergothioneine transporter do not accumulate the compound at all, because the plasma membrane is virtually impermeable to it.^[4] Ergothioneine measured inside a tissue is therefore evidence that a transporter put it there. Shukla's 1981 measurements found ergothioneine in human lenses, so some transporter-mediated route into the lens must exist.

Where that route runs is the part the literature has not settled. Gründemann's 2022 inventory of ergothioneine transporter locations is explicit that the transporter is not expressed ubiquitously, and that only cells with high surface levels of it accumulate the compound. The sites it documents as prominent are neutrophils, monocytes and macrophages, and developing erythrocytes.^[2] Lens epithelium is not among the expression sites that inventory establishes, and no published study has directly demonstrated the ergothioneine transporter in lens epithelial cells.

This is worth stating plainly, because a good deal of secondary writing on this topic asserts that the lens has its own dedicated ergothioneine import machinery. The lens demonstrably contains ergothioneine, and that ergothioneine demonstrably had to be transported. The specific claim that lens epithelial cells express the transporter themselves is an inference that has not been tested.

Cheah and Halliwell's 2021 review supplies the broader pattern that makes this worth pursuing: ergothioneine accumulates to high levels in the body from diet, and blood levels decline with age and with the onset of various diseases.^[3] An antioxidant that depletes with age is a reasonable suspect in a disease of aging.

For a detailed look at how the lens's unusual anatomy shapes its entire antioxidant strategy, see Ergothioneine and Eye Health: Why Your Lens Contains It.

OCTN1: A Transporter the Body Built for a Single Compound

In 2005, Gründemann and colleagues at the University of Cologne identified OCTN1 (SLC22A4) as the specific, dedicated transporter for ergothioneine.^[4] This was a landmark discovery: the human body maintains an entire molecular import system whose principal job is moving one dietary compound.

OCTN1 is not a general-purpose antioxidant transporter. Ergothioneine is transported more than a hundred times more efficiently than the organic cations the protein was originally assumed to carry, and the related carnitine transporter OCTN2 does not move ergothioneine at all. The specificity is the point, which is why the same team proposed renaming the protein ETT, for ergothioneine transporter.

The existence of this dedicated system carries a broader implication. In 2018, biochemist Bruce Ames proposed a category he called "longevity vitamins" — nutrients required not for immediate survival but for long-term protection against age-related damage. Under his triage theory, a modest shortfall of such a nutrient is rationed away from long-term protection first, so deficiency shows up not as acute illness but as an insidious acceleration of aging-associated disease. Ames named ergothioneine explicitly among the compounds he considered putative longevity vitamins.^[5]

That framework fits the lens well, though fitting a framework is not the same as being demonstrated within it. The lens is a tissue where damage accumulates silently over decades and where the consequence arrives late in life — precisely the profile Ames' triage argument describes. Ergothioneine reaches the lens, blood levels of it fall with age, and cataractous lenses contain less of it. Whether those facts form a causal chain is exactly what has not been established.

3 Mechanisms Linking Ergothioneine to Cataract Prevention

The mechanism isn't a single pathway. Research identifies at least three distinct approaches, each targeting a different aspect of UV-induced oxidative injury in the lens.

Singlet oxygen quenching. UV light generates singlet oxygen directly in the lens, a highly reactive oxygen species that oxidizes crystallin proteins. Ergothioneine is an effective quencher of singlet oxygen, a property covered in Cheah and Halliwell's 2021 review of the compound's antioxidant chemistry.^[3] This matters in a tissue where singlet oxygen is a principal threat, though it should be noted that this chemistry has been characterized in laboratory systems rather than in living human lenses.

Metal ion chelation. The lens accumulates trace amounts of iron and copper over time. These metals catalyze the Fenton reaction, which converts hydrogen peroxide — already present from UV exposure — into the hydroxyl radical, one of the most destructive oxidants in biology. Ergothioneine is characterized as an intracellular antioxidant with metal ion affinity, binding such metals and limiting their capacity to catalyze further damage.^[4][3] This mechanism would become progressively more relevant as the lens ages and metal accumulation increases.

Nrf2 pathway activation. In 2024, Li and colleagues demonstrated that ergothioneine protects cells against UV-induced oxidative stress through the PI3K/AKT/Nrf2 signaling pathway.^[6] Nrf2 is the cell's master regulator of antioxidant response. When it activates, it switches on dozens of genes involved in antioxidant synthesis and oxidative damage repair. In that work, ergothioneine lowered markers of oxidative damage and raised antioxidant enzyme activity in UV-exposed mouse skin, and blocking PI3K abolished the protection — which is what makes the pathway attribution credible rather than merely correlational.

The important caveat is the model. Li's work was done in mouse skin and cultured skin cells, not in lens tissue. Nrf2 signaling does operate in lens epithelial cells, so the pathway is plausibly relevant, but no one has run the equivalent experiment in a lens. This is an extrapolation, and it should be read as one.

These three mechanisms address distinct threats: the singlet oxygen generated by UV absorption, the metal-catalyzed radical chemistry in aging lens tissue, and the broader cellular response to sustained oxidative stress. Ergothioneine's breadth — acting at three separate points in the damage cascade — is what makes it an interesting candidate for a tissue that has to defend itself continuously for a lifetime without the option of replacing what gets damaged.

The Human Evidence: What Cataractous Lenses Actually Contain

The most direct evidence connecting ergothioneine to cataracts comes from Shukla and colleagues' study published in the Indian Journal of Medical Research in 1981.^[1] They examined ergothioneine content in lens tissue from cataract patients and compared it to tissue from age-matched controls with normal vision.

Cataractous lenses had markedly lower ergothioneine.

This finding is easy to overstate or understate. Here is what it actually tells us and doesn't tell us.

What it tells us: there was a clear, measurable difference in ergothioneine content between lenses that had developed cataracts and lenses that had not. This is human tissue data from actual patients, not a cell line or an animal model. The association between lower ergothioneine and lens opacity was directly observed in human biology rather than inferred from a model system.

What it doesn't tell us: the study is observational and cross-sectional. It cannot establish whether low ergothioneine causes cataracts, whether the cataract formation process itself depletes ergothioneine, or whether some third factor drives both. That last possibility deserves more weight than it usually gets. Ergothioneine comes entirely from diet, and blood levels fall with age and with the onset of disease generally — so a cataract patient with less lens ergothioneine may be showing the signature of poorer diet, older age, or worse overall health rather than a lens-specific deficit. No randomized trial has shown that ergothioneine supplementation prevents cataracts in humans.

It is also a single study from 1981, in a small literature, and it has not been repeated in the four decades since. A finding that has never been replicated should be held more loosely than one that has.

Much of the web content claiming ergothioneine "prevents cataracts" cites this study and overstates it. The accurate claim is narrower: cataractous human lenses contain markedly less ergothioneine than normal lenses; ergothioneine reaches the lens by active transport, though the route has not been mapped; and the mechanisms by which ergothioneine counters UV-driven oxidation are characterized in laboratory systems and, for the Nrf2 pathway, in skin rather than lens models. That is a coherent and meaningful body of evidence. It is not the same as clinical proof of prevention.

Being precise about what a 1981 cross-sectional tissue study can and cannot show is what distinguishes research reporting from marketing.

No Human Trial Yet: What We Know and What We Don't

The mechanistic case is well-developed. The intervention evidence is absent.

Evidence Map

Ergothioneine & Cataracts — A Solid Chemical Base Under Four Empty Rungs

This is an inverted ladder. What is best established sits at the bottom — the transporter and the antioxidant chemistry. What the prevention claim actually requires sits at the top, and all of it is missing. Bar width reflects how close each tier sits to a proven human outcome. Solid bars are demonstrated findings, half-tone bars are real results that have to be extrapolated to reach the lens, and dashed bars are gaps — including the commonly-repeated claim that the lens has its own ergothioneine transporter, which has never been shown.

Human trial: does ergothioneine prevent cataracts?

gap

Does not exist

No randomized controlled trial has tested whether ergothioneine supplementation reduces cataract incidence or slows progression. Cataracts develop over decades, so an adequately powered trial would be long and expensive — and it has not been attempted

Does supplementation raise ergothioneine in the lens?

gap

Never measured

The link every prevention claim depends on, and it has never been measured. Nobody has shown how much dietary ergothioneine reaches the human lens, how fast, or whether taking more changes lens concentrations at all

Is the ergothioneine transporter in lens epithelium?

gap

Not demonstrated · Gründemann 2022

Widely asserted in secondary writing, but not demonstrated. The 2022 inventory of transporter locations is explicit that expression is not ubiquitous, and documents neutrophils, monocytes/macrophages and developing erythrocytes — not lens epithelium. How ergothioneine crosses into the lens is unresolved

Replication of the human tissue finding

gap

Never repeated

The 1981 depletion result has not been repeated in the four decades since. A single unreplicated cross-sectional study is the entire human evidence base for the association

Human observation: cataractous lenses are depleted

evidence

Shukla 1981

Ergothioneine content was markedly lower in cataractous human lenses than in age-matched normal lenses. Real human tissue, not a cell line — but cross-sectional, so it cannot separate cause from consequence from a third factor such as age or diet

Ergothioneine reaches the lens only by active transport

evidence

Gründemann 2005

Cell membranes are virtually impermeable to ergothioneine, and cells without the transporter do not accumulate it at all. So measurable ergothioneine inside lens tissue is itself proof that a transporter delivered it — even though the route has not been mapped

A dedicated, ergothioneine-specific transporter exists

evidence

Gründemann 2005 · Gründemann 2022

OCTN1/ETT (SLC22A4) carries ergothioneine more than a hundred times more efficiently than the organic cations it was assumed to transport, and the related carnitine transporter OCTN2 does not carry it at all. The body maintains an import system for essentially one dietary compound

Antioxidant chemistry relevant to lens damage

extrapolated

Cheah & Halliwell 2021 · Gründemann 2005

Ergothioneine quenches singlet oxygen — the species UV generates in the lens — and has metal ion affinity, limiting the iron- and copper-catalyzed chemistry that turns hydrogen peroxide into hydroxyl radicals. Characterized in laboratory systems rather than in living human lenses

Nrf2 protection under UV stress — but in skin

extrapolated

Li 2024 (skin model)

Ergothioneine reduced oxidative damage markers and activated PI3K/AKT/Nrf2 signaling in UV-exposed mouse skin, and blocking PI3K abolished the protection. Convincing within its model, but the experiment has never been run in lens tissue

Longevity-vitamin framework

extrapolated

Ames 2018

Ames named ergothioneine among putative "longevity vitamins" — nutrients supporting long-term protection rather than immediate survival, whose shortfall shows up as accelerated age-related damage. A framework for interpreting the evidence, not evidence itself

How to read it: read this ladder from the bottom up. The foundation is genuinely strong — there is a dedicated transporter for this one compound, and ergothioneine cannot enter any cell without it, so the ergothioneine measured in human lenses proves active delivery. Above that sits one real human observation from 1981: cataractous lenses were depleted. Everything higher is empty. The finding was never replicated, the transporter has never been located in lens epithelium, the dose-to-lens link has never been measured, and no trial has been run. A strong mechanism at the bottom does not carry the weight of the missing rungs above it. Nothing here is medical advice.

Sources: Shukla 1981 [1]; Gründemann 2022 [2]; Cheah & Halliwell 2021 [3]; Gründemann 2005 [4]; Ames 2018 [5]; Li 2024 [6]. Bar widths are illustrative of proximity to a proven human outcome, not quantitative effect sizes.

No human randomized controlled trial has tested whether ergothioneine supplementation reduces the incidence or rate of progression of cataracts. The studies available are a single 1981 cross-sectional tissue analysis, mechanistic characterization of ergothioneine's antioxidant chemistry in laboratory systems, and 2024 UV stress research conducted in skin. Each piece is informative. None constitutes clinical proof that supplementation works in humans.

There is also a gap earlier in the chain than the trials. No one has shown how much dietary ergothioneine actually reaches the human lens, how quickly, or whether supplementation raises lens concentrations at all. A trial testing whether ergothioneine prevents cataracts presumes a dose-to-tissue relationship that has not been measured.

This gap exists partly because cataracts develop over decades. A properly powered clinical trial would need to follow participants for years and would be expensive to run. That work hasn't been done for ergothioneine yet.

Ames' 2018 framework offers one way to think about acting under this kind of uncertainty: he argued that nutrients supporting long-term protective functions can be biologically important — and their shortfall genuinely damaging — even where the long-horizon trials confirming it are impractical to run.^[5] That is a defensible scientific position about how to weigh mechanistic evidence. It is not a substitute for clinical proof, and Ames did not claim it was.

Current state: reasonable mechanistic plausibility, one unreplicated human tissue observation from 1981, an unmapped route into the lens, and no intervention trials in humans. Enough to take seriously as a research question; not enough to make clinical claims.

Nothing here is medical advice. If you are concerned about cataracts or changes in your vision, that is a conversation for an ophthalmologist or your physician — cataracts are diagnosed by examination and treated effectively with surgery, and no dietary compound is an established alternative to that care.

Mushrooms: The Primary Dietary Source of Ergothioneine

Ergothioneine is synthesized almost exclusively by fungi. Bacteria produce trace amounts, but mushrooms are the practical dietary source for humans.

Ergothioneine content varies by species. Porcini, oyster mushrooms, and maitake contain substantially higher concentrations than common button mushrooms. For the most detailed breakdown by species, see Ergothioneine Content by Mushroom Species: A Complete Ranking.

For the full story on why fungi are the only meaningful biosynthetic source, see Why Only Fungi Make Ergothioneine (And Why That Matters).

Ergothioneine is heat-stable and survives normal cooking. After absorption from the digestive tract via OCTN1 transporters in intestinal cells, it enters the bloodstream and is distributed to tissues that express the transporter. The final steps of that journey — how ergothioneine crosses into the aqueous humor and then into the lens, and which transporters carry it there — have not been directly established. How much of a typical dietary dose accumulates in the human lens, and over what time frame, has not been measured in humans either. Those are open questions, and they are the questions that would need answering before anyone could design a serious prevention trial.

The Bottom Line

Cataractous human lenses contain markedly lower ergothioneine than normal lenses, in a single 1981 tissue study that has not been replicated. Ergothioneine cannot cross cell membranes unaided, so its presence in the lens means active transport delivered it — but the specific route into the lens has not been mapped, and the claim that lens epithelial cells express the ergothioneine transporter themselves is an untested inference rather than a documented finding. Three protective mechanisms are characterized in laboratory systems: singlet oxygen quenching, metal chelation, and Nrf2 pathway activation under UV stress, the last of these demonstrated in skin rather than lens. Current evidence is observational and mechanistic; no human intervention trial has tested whether ergothioneine supplementation reduces cataract incidence or progression. This is not medical advice.

Frequently Asked Questions

Can ergothioneine prevent cataracts?

No human randomized controlled trial has tested this, so the honest answer is that nobody knows. What the evidence shows is narrower than the question: cataractous human lenses contained markedly lower ergothioneine than normal lenses in one 1981 study that has not been replicated; ergothioneine reaches the lens by active transport, because cell membranes are impermeable to it without a transporter; and ergothioneine counters UV-driven oxidative chemistry through three mechanisms characterized in laboratory systems. Whether supplementing raises lens ergothioneine at all, let alone enough to reduce cataract risk, has not been tested. This is not medical advice.

What supplements may reduce cataract risk?

No supplement has been established to prevent cataracts, and this is a question for a physician rather than an article. Antioxidants that counter UV-driven lens protein oxidation are the most-studied category: vitamins C and E have been tested in large trials with mixed and largely disappointing results, which is itself a caution against assuming that a promising antioxidant mechanism translates into a clinical benefit. Ergothioneine is a newer candidate with an interesting mechanistic profile — singlet oxygen quenching, metal ion chelation, and Nrf2 pathway activation — and one 1981 human tissue observation of depletion in cataractous lenses. It has not been tested in a cataract trial. This is not medical advice.

What causes cataracts at the molecular level?

Cataracts form when crystallin proteins in the lens become oxidized, aggregate, and scatter light. Because lens proteins are never replaced during a person's lifetime, every oxidative injury that isn't neutralized in real time is permanent. The primary trigger is UV light, which generates singlet oxygen and hydrogen peroxide directly in the lens. Metal ions (iron, copper) in the aging lens amplify the damage through Fenton chemistry, converting hydrogen peroxide into the highly destructive hydroxyl radical. Cumulative, irreversible oxidative damage to proteins that can never be replaced is the fundamental mechanism.

What is the role of oxidative stress in cataract formation?

Oxidative stress is the central driver. UV radiation generates reactive oxygen species including singlet oxygen and hydrogen peroxide in the lens tissue. These species oxidize crystallin proteins, causing them to unfold and clump together. Because the lens cannot replace damaged proteins and has no direct blood supply for antioxidant delivery, its defense depends on antioxidants reaching it through the aqueous humor — glutathione, vitamin C, and ergothioneine among them. Decades of cumulative, unrepaired oxidative damage produce the opacity characteristic of a cataract.

Do mushrooms help prevent cataracts?

No study has tested this. Mushrooms are the primary dietary source of ergothioneine, ergothioneine is present in lens tissue, and cataractous lenses were found depleted of it in one 1981 study. But the chain from eating mushrooms to a protected lens has several unmeasured links: whether dietary intake raises lens ergothioneine, by how much, and whether higher lens levels reduce cataract risk are all unanswered. Mushrooms are a nutritious food and there is no reason to avoid them; treating them as cataract prevention goes well beyond what the evidence supports. This is not medical advice.

Sources & References

1. 1RTHM-00004·Shukla, Y et al. (1981). “Ergothioneine content in normal and senile human cataractous lenses..” The Indian journal of medical research.Study breakdown →PubMed →↩
2. 2RTHM-01527·Gründemann, Dirk et al. (2022). “The ergothioneine transporter (ETT): substrates and locations, an inventory..” FEBS letters.Study breakdown →PubMed →↩
3. 3RTHM-00678·Cheah, Irwin K et al. (2021). “Ergothioneine, recent developments..” Redox biology.Study breakdown →PubMed →↩
4. 4RTHM-00154·Gründemann, Dirk et al. (2005). “Discovery of the ergothioneine transporter..” Proceedings of the National Academy of Sciences of the United States of America.Study breakdown →PubMed →↩
5. 5RTHM-00936·Ames, Bruce N (2018). “Prolonging healthy aging: Longevity vitamins and proteins..” Proceedings of the National Academy of Sciences of the United States of America.Study breakdown →PubMed →↩
6. 6RTHM-01933·Li, Yongchao et al. (2024). “Ergothioneine Protects Against UV-Induced Oxidative Stress Through the PI3K/AKT/Nrf2 Signaling Pathway..” Clinical.Study breakdown →PubMed →↩